United StatesHealth

Milestone Pharmaceuticals (NASDAQ:MIST) has officially moved into the commercial stage with the U.S. retail launch of Cardamyst™ (etripamil).

SciSparc (NASDAQ:SPRC), a company traditionally focused on cannabinoid-based pharmaceuticals, has officially pivoted into the medical device sector.

Mirum Pharmaceuticals (NASDAQ:MIRM) announced the successful closing of its acquisition of Bluejay Therapeutics, a move that significantly broadens its rare disease pipeline with a potential first-in-class therapy for chronic hepatitis delta virus (HDV).

United Therapeutics (NASDAQ:UTHR) has cleared a primary safety hurdle in its ambitious effort to manufacture biological alternatives to human organs, reporting that its bioengineered external liver supported critically ill patients without serious adverse effects.

MannKind (NASDAQ:MNKD) received U.S. Food and Drug Administration approval on Monday for a critical update to the prescribing information for Afrezza, its inhaled mealtime insulin.

Biogen (NASDAQ:BIIB) and Eisai have cleared a significant regulatory hurdle as the U.S. Food and Drug Administration (FDA) accepted their supplemental Biologics License Application for a subcutaneous version of the Alzheimer’s treatment Leqembi.

Bausch Health Companies (NYSE:BHC) today announced results from its global Phase 3 RED-C clinical program evaluating amorphous-rifaximin SSD for the primary prevention of hepatic encephalopathy (HE) in adults with liver cirrhosis.

Sanara MedTech (NASDAQ:SMTI) announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with initial guidance for 2026.

OKYO Pharma (NASDAQ:OKYO) announced that the U.S. Food and Drug Administration has authorized a single-patient expanded access Investigational New Drug application (IND 176297) for urcosimod 0.05% to treat a patient with severe neuropathic corneal pain (NCP).

ImmunityBio (NASDAQ:IBRX) reported updated Phase 2 clinical results for its novel immunotherapy combination in patients with recurrent glioblastoma, suggesting the treatment may overcome the "immune collapse" that typically follows standard cancer therapies.

Plus Therapeutics (NASDAQ:PSTV) on Thursday detailed a strategic shift toward "pivotal trial readiness," supported by a recently completed $15 million public offering designed to extend the company’s cash runway into 2027.

Janux Therapeutics (NASDAQ:JANX) shares surged as much as 12% in early trading Thursday following the announcement of a global licensing deal with Bristol Myers Squibb (NYSE:BMY) worth up to $850 million.